Prosecution Insights
Last updated: November 04, 2026
Application No. 19/110,297

ANTI-TUMOR IMMUNE RESPONSE ENHANCER

Non-Final OA §101§102§103§112
Filed
Mar 10, 2025
Priority
Sep 12, 2022 — JP 2022-144313 +1 more
Examiner
KASAYAN, KATRIEL BARCELLANO
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kenichiro Hasumi
OA Round
1 (Non-Final)
25%
Grant Probability
At Risk
1-2
OA Rounds
1y 7m
Est. Remaining
25%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
1 granted / 4 resolved
-35.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
35 currently pending
Career history
38
Total Applications
across all art units

Statute-Specific Performance

§101
6.5%
-33.5% vs TC avg
§103
40.3%
+0.3% vs TC avg
§102
7.9%
-32.1% vs TC avg
§112
38.9%
-1.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 4 resolved cases

Office Action

§101 §102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . STATUS OF CLAIMS This action is in response to papers filed on March 10, 2025. Pursuant to preliminary amendment claims 1-11 are pending. Claims 1-8 have been amended and claims 9-11 have been added by applicants’ amendment filed on 3/10/2025. Therefore, claims 1-11 are under examination to which the following grounds of rejection are applicable. Claims 1, 8 and 11 are independent claims. Priority The instant application is a 35 U.S.C. 371 national stage filing of International Application PCT/JP2023/030929 filed on August 28, 2023. The International Application claims priority to Japanese Application 2022-144313, filed September 12, 2022. Therefore, the earliest effective filing date for the instant application is September 12, 2022. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 2, 3, 4 and by dependency claims 5, 9, 10, 11 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example Ex parte Dunki, 153 USPQ 678 (Bd.App. 1967) and Clinical Products, Ltd. v. Brenner, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966). Claim 2 provides for a method of using the anti-tumor immune response enhancer for growth suppression of a tumor in a subject. Claim 3 provides for a method of using the anti-tumor immune response enhancer for inducing an immature dendritic cell to be a mature dendritic cell. Claim 4 provides for a method of using the anti-tumor immune response enhancer for inducing an immature dendritic cell to be CDI lb+ CDI 1c+ viable cells. Since the claims do not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 3-5 9, 10, and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 2, 3, 4 and by dependency claims 5, 9, 10, 11 are indefinite since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. Regarding claim 3, the terms “mature” and “immature” are relative terms which renders the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Regarding claim 4, the terms “mature” and “immature” are relative terms which renders the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Regarding claim 5, the term “immature” is a relative term which renders the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Regarding claim 8, the term “immature” is a relative term which renders the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Regarding claim 11, the term “immature” is a relative term which renders the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Claim Rejections - 35 USC § 112, Written Description The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1- rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. M.P.E.P. § 2163 recites, "The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice (see i)(A), above), reduction to drawings (see i)(B), above), or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus (see i)(C), above). See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406." Further, the written description inquiry is limited to that which is contained within the four corners of the specification, not the extent to which the skilled artisan, given his or her knowledge of the art, would have considered it to expand with only routine experimentation. See Ariad Pharms. Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en bane); see also id. At 1352 ("[I]t is the specification itself that must demonstrate possession. A description that merely renders the invention obvious does not satisfy the requirement."). Claim 1 is drawn to an anti-tumor immune response enhancer comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine, without limiting their concentrations or relative proportions with the intended use preparing mature dendritic cells (claim 8 and 11) . There is not structure/function correlation for the claimed genus of claimed enhancers comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine in suppressing the tumor in a subject. The disclosure fails to teach any species within the genus, nor does it define any structural or functional characteristics that distinguish anti-tumor immune response enhancers comprising phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS) from other compositions. Moreover, there is only one working example of a percentage composition of these components, wherein the mass ratio of PC:PE:PS is 14:3:3, which translates to 70% PC, 15% PE and 15% PS (para 0037). Therefore, the specification does not provide representative working examples demonstrating anti-tumor immune response enhancement across this broader range of compositions. The prior art demonstrates that different phospholipids within compositions can influence immune responses. Chen et al. (Published: 2004. Journal of immunology (Baltimore, Md. : 1950), 173(5), 2985–2994.) studies the impact phosphatidylcholine and phosphatidylserine has on dendritic cell maturation (pp. 2985, Abstract). Moreover, Chen teaches that inhibition of dendritic cell maturation was dose-dependent for PS liposomes (pp. 2987, right col para 1 and Figure 1B). Therefore, the prior art establishes that varying concentrations of phosphatidylserine concentrations can elicit different immunological effects, such as dendritic cell maturation. PNG media_image1.png 252 732 media_image1.png Greyscale The specification as filed provides one example where PC, PE and PS were dissolved in ethanol in a mass ratio of PC:PE:PS=14:3:3. Specifically, 0.84 mg of PC, 0.18 mg of PE, and 0.18 mg of PS were dissolved in 1 mL of ethanol to prepare 1.2 mg/mL of lipid composition cPLs adjuvant (para 0037). The specification also reveals that at this concentration, the cPL adjuvant was administered to MO4-implanted mice in a dose of 12mg/kg, and tumor volumes decreased by nearly half the size of the untreated control tumors (para 0043). Although the disclosure provides one example of the specific proportions of PC, PE and PS, claim 1 broadly encompasses compositions comprising these phospholipids in any amount. As such, the limited disclosure does not reasonably convey that the inventors were in possession of the full scope of the anti-tumor immune response enhancer. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-5, 8 and 11 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Dobbie et al. (Published: 2012. European Patent: EP1267924B1. ref. of record. Cited in IDS filed 10/01/2026). Regarding claim 1, Dobbie teaches cancer therapy (para 0002) comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (Dobbie; para 0012, para 0013, claim 1, claim 2). Regarding claim 2, The limitation “used for growth suppression of a tumor in a subject” is intended use. If the prior art composition taught by primary reference is capable of performing the recited intended use, this limitation is met. See e.g. In re Schreiber, 128 F.3d 1473, 1477; 44 USPQ2d 1429, 1431 (Fed. Cir. 1997); MPEP 2114. Regarding claim 3, the limitation “used for inducing an immature dendritic cell to be a mature dendritic cell” is intended use. If the prior art composition taught by primary reference is capable of performing the recited intended use, this limitation is met. See e.g. In re Schreiber, 128 F.3d 1473, 1477; 44 USPQ2d 1429, 1431 (Fed. Cir. 1997); MPEP 2114. Regarding claim 4 and 5, the limitation “used for inducing an immature dendritic cell to be CD11b+ CD11c+ viable cells” (instant claim 4) and “wherein the immature dendritic cell is an immature conventional dendritic cell or a tumor-associated dendritic cell” (instant claim 5) is intended use. If the prior art composition taught by primary reference is capable of performing the recited intended use, this limitation is met. See e.g. In re Schreiber, 128 F.3d 1473, 1477; 44 USPQ2d 1429, 1431 (Fed. Cir. 1997); MPEP 2114. Regarding claims 8 and 11, Dobbie teaches that the dendritic cells are cultured and combined with the phospholipid vesicles to yield modified dendritic cells (para 0041). Therefore, by teaching all the limitations of the claims as written, Dobbie anticipates the claimed invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1, 2, 6 , and 9 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dobbie et al. (Published: 2012. European Patent: EP1267924B1. Cited in IDS filed 10/01/2026). Regarding claim 1 and 2, Dobbie teaches a cancer therapy (para 0002) comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (Dobbie; para 0012, para 0013, claim 1, claim 2). Dobbie also teaches that the dendritic cells are cultured and combined with the phospholipid vesicles to yield modified dendritic cells (para 0041). Moreover, Dobbie teaches the anti-tumor immune response agent to comprise 54% phosphatidylcholine, 8% phosphatidylethanolamine, and the composition of phosphatidylserine can range from 2-6%, but preferably 4% (para 0012; para 0013). Dobbie also teaches that the phospholipid vesicles are constructed using specific phospholipids in proportions similar to lamellar bodies found in normal tissues (para 0044), and show light variation based on the cell of origin (para 0045). However, Dobbie does not explicitly teach a composition an embodiment of phosphatidylserine within the claimed range of 5-25%, as required by claims 6 and 9. Therefore, it would have been obvious to optimize aspects of the phospholipid vesicle to comprise a percentage composition of phosphatidylserine within the claimed range, as Dobbie establishes that the proportions could be modified to reflect the composition of lamellar bodies found in tissue. A skilled artisan would have been motivated to modify the composition to more accurately represent its biological counterpart. A skilled artisan would have had a reasonable expectation of success as controlling the concentration of PC, PE and PS to reflect the composition of lamellar bodies was known in the art before the effective filing date of the claimed invention. The Court has stated that generally such differences amount to mere optimization and will not support patentability unless there is evidence indicating the claimed feature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). (Claimed process which was performed at a temperature between 40°C and 80°C and an acid concentration between 25% and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100°C and an acid concentration of 10%.); see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); In re Hoeschele, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969) (Claimed elastomeric polyurethanes which fell within the broad scope of the references were held to be unpatentable thereover because, among other reasons, there was no evidence of the criticality of the claimed ranges of molecular weight or molar proportions.). For more recent cases applying this principle, see Merck & Co. Inc. v. Biocraft Laboratories Inc., 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); In re Kulling, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and In re Geisler, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). In KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007), the Supreme Court held that "obvious to try" was a valid rationale for an obviousness finding, for example, when there is a "design need" or "market demand" and there are a "finite number" of solutions. 550 U.S. at 421. MPEP § 2144 sets forth Applicant' s burden for rebuttal of a prima facie case of obviousness based upon routine optimization. Applicant must provide either a showing that the particular amount or range recited within the claims is critical; and/or a showing that the prior art reference teaches away from the claimed amount. *** Claim(s) 1, 2, 7 and 10 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dobbie et al. (Published: 2012. European Patent: EP1267924B1. ref. of record. Cited in IDS filed 10/01/2026) in view of Thanou et al. (Published: 2018. US Patent App. US 20180177728 A1). With regard to claim 1 and 2, the teachings of Dobbie render obvious the claimed methodology, as iterated above in the 103 rejection the content of which is incorporated herein, in its entirety. Dobbie teaches a cancer therapy (para 0002) comprising phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (Dobbie; para 0012, para 0013, claim 1, claim 2). However, Dobbie does not teach that the anti-tumor immune response enhancer further comprises one or more anticancer agents, as required by claims 7 and 10. Thanou teaches a lipid nanoparticle comprising at least one phospholipid (abstract), wherein the phospholipid can be phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine (para 0091). Thanou teaches that the lipid nanoparticle can comprise an active pharmaceutical ingredient (para 0017), wherein the ingredient can be an anticancer agent (para 0285). Thanou also teaches that these agents are capable of inducing cancer cell or tumor cell toxicity (para 0285). Therefore, a person would have been motivated to modify the anti-tumor immune response enhancer of Dobbie to further comprise an anticancer agent, as taught in Thanou, for inducing cancer cells and tumor cell cytotoxicity. There would have been reasonable expectations of success in combining these teachings as one of ordinary skill in the art would recognize to combine known elements in the art to give predictable results. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katriel B Kasayan whose telephone number is (571)272-1402. The examiner can normally be reached 10-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria G Leavitt can be reached at (571) 272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATRIEL BARCELLANO KASAYAN/Examiner, Art Unit 1634 /MARIA G LEAVITT/Supervisory Patent Examiner, Art Unit 1634
Read full office action

Prosecution Timeline

Mar 10, 2025
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
25%
Grant Probability
25%
With Interview (+0.0%)
3y 3m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month